- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | InterCure secures $18.2M for post-war recovery | 2 | Investing.com | ||
| Fr | Intercure Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 25.11. | Intercure Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 04.11. | Intercure Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| INTERCURE Aktie jetzt für 0€ handeln | |||||
| 28.10. | Intercure Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 13.09. | Intercure Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 30.08. | InterCure reports 1H results | 1 | Seeking Alpha | ||
| 30.08. | InterCure Ltd.: InterCure Announces First Half of 2024 Results: Revenue of NIS 126 million and Adjusted EBITDA of NIS 21 million | 759 | GlobeNewswire (Europe) | Revenues during the first half of 2024 reached NIS 126 million, alongside an Adjusted EBITDA1of NIS 21 million (Approximately 17% of revenues).Both quarters (Q1 and Q2 of 2024) ended with positive... ► Artikel lesen | |
| 28.08. | InterCure partners with Cookies to launch cannabis pharmacies in Germany | 1 | Investing.com | ||
| 28.08. | InterCure expands strategic partnership with Cookies to Germany | 1 | Seeking Alpha | ||
| 28.08. | InterCure Announces Expansion of its Strategic partnership with Cookies to Germany | 233 | Business Wire | InterCure expands its European footprint to launch Cookies Corners licensed pharmacies in Germany alongside differentiated online platforms with the official cookies retail experience, enhancing... ► Artikel lesen | |
| 28.08. | Intercure Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 01.05. | InterCure Announces FY2023 Results: Revenue of NIS 356 million and Adjusted EBITDA of NIS 61 million | 255 | Business Wire | NEW YORK & HERZLIYA, Israel--(BUSINESS WIRE)--InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) ("InterCure" or the "Company") today announced results for the full year ending December 31, 2023. All amounts... ► Artikel lesen | |
| 01.04. | InterCure Announces Preliminary Estimated 2023 Revenue of NIS 351 million and EBITDA of over NIS 50 million | 406 | Business Wire | NEW YORK & HERZLIYA, Israel--(BUSINESS WIRE)--InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) ("InterCure" or the "Company") today announced preliminary results for the full year of 2023. All amounts... ► Artikel lesen | |
| 22.03. | InterCure Ltd.: InterCure Congratulates Germany on Cannabis Reform, Expanding its Global Footprint | 493 | Business Wire | InterCure provides an update following recent Cannabis Reform in Germany Expects to launch its first products in Germany in the coming months The Company continues to closely watch... ► Artikel lesen | |
| 31.01. | InterCure Ltd.: InterCure Signs Definitive Agreement to Acquire Leon Cannabis Pharmacy Chain | 286 | GlobeNewswire (Europe) | NEW YORK, and HERZLIYA, Israel, Jan. 31, 2024 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the leading medical cannabis company in Israel... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ASTRIA THERAPEUTICS | 9,560 | +1,16 % | Astria Therapeutics, Inc. - 8-K, Current Report | ||
| ROCKET LAB USA | 23,900 | 0,00 % | Space Technology: Rocket Lab stellt zweites Raumfahrzeug für Varda Space Industries fertig | ||
| BOIRON | 26,600 | -0,19 % | BOIRON: EVOLUTION OF GOVERNANCE | July 3rd, 2024
The Board of Directors of Laboratoires BOIRON, meeting today under the chairmanship of Thierry BOIRON, has enacted an evolution of the Group's governance.
In this context, Thierry... ► Artikel lesen | |
| HARROW | 34,220 | -0,61 % | Harrow Health Aktie: Stabile Aussichten? | Der Aktienkurs des Augenheilkunde-Spezialisten Harrow Health verzeichnete am 07. Dezember einen bemerkenswerten Anstieg von 5,08 Prozent auf 39,32 USD. Die Entwicklung steht im Kontrast zum negativen... ► Artikel lesen | |
| ESSA PHARMA | 1,610 | +0,31 % | ESSA Pharma Inc: ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2024 | Company has initiated a process to explore and review strategic options focused on maximizing shareholder value
SOUTH SAN FRANCISCO, California and VANCOUVER... ► Artikel lesen | |
| MEDICINOVA | 2,020 | 0,00 % | MediciNova, Inc.: MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND | LA JOLLA, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 3,650 | +0,27 % | Aquestive receives FDA Orphan Drug Exclusivity for Libervant | ||
| REVIVA PHARMACEUTICALS | 1,335 | -11,00 % | Reviva announces pricing of $18M public offering of common stock and warrants | ||
| SHINECO | 2,240 | +10,89 % | Shineco, Inc.: Shineco Regains Compliance with Nasdaq Minimum Bid Price Requirement | BEIJING, June 27, 2024 (GLOBE NEWSWIRE) -- Shineco Inc. ("Shineco" or the "Company"; NASDAQ: SISI), a producer of innovative diagnostic medical products and related medical devices, announced today... ► Artikel lesen | |
| LYRA THERAPEUTICS | 0,180 | +5,71 % | Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update | Company continues to focus on upcoming results from ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients expected in 2Q 2025 Company reports topline safety results from ENLIGHTEN 1 Phase 3 extension... ► Artikel lesen | |
| CUMBERLAND PHARMACEUTICALS | 2,280 | -1,72 % | Cumberland Pharmaceuticals Inc.: FDA Approves Acetadote sNDA | - New Dosing Regimen Simplifies Administration -
NASHVILLE, Tenn., Dec. 9, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty... ► Artikel lesen | |
| CYANOTECH | 0,260 | 0,00 % | CYANOTECH CORP - 8-K, Current Report | ||
| ONKURE THERAPEUTICS | 8,160 | +1,12 % | OnKure Therapeutics, Inc.: OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219 | -- OKI-219 is well-tolerated across all doses, and no dose interruptions, delays, reductions, or discontinuations were reported -- Initial patient data show exposures of OKI-219 exceeding levels associated... ► Artikel lesen | |
| BAYER | 18,936 | +0,35 % | Dividendenperlen: Nicht Super Micro & Bayer: 3 Wachstums-Dividendenaktien für 2025 & darüber hinaus | Das aktuelle Börsenjahr nähert sich dem Ende. Welche Aktien könnten zukünftig gut abschneiden? 2024 war trotz geopolitischer Konflikte, Rezessionstendenzen und politischer Turbulenzen bisher ein sehr... ► Artikel lesen | |
| MERCK KGAA | 138,20 | -0,18 % | Merck Aktie: Sprung in neue Höhen! | Die Merck-Aktie verzeichnete am Handelstag einen deutlichen Rückgang und bewegte sich im XETRA-Handel auf 139,95 Euro abwärts. Dies entspricht einem Minus von 0,9 Prozent, wobei das Tagestief bei 139... ► Artikel lesen |
Das Unternehmen INTERCURE LTD kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,120 (+8,96 %) liegt der Kurs bei 1,460 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INTERCURE LTD finden Sie auf Wallstreet Online.
